share_log

Nano X Imaging | 6-K: Report of foreign private issuer (related to financial reporting)

Nano X Imaging | 6-K: Report of foreign private issuer (related to financial reporting)

Nano X Imaging | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  2024/11/21 21:09

Moomoo AI 已提取核心訊息

Nanox reported Q3 2024 revenue of $3.0 million, up from $2.5 million in Q3 2023, driven by growth in teleradiology services and AI solutions. The company posted a net loss of $13.6 million, an improvement from $21.4 million loss in the prior year period, primarily due to reduced impairment expenses.The company continued expanding its US sales and support teams while making progress in global deployment of Nanox.ARC systems. The Nanox.AI business secured new distribution agreements with SpinexMedical and extended partnerships with major healthcare providers including Corewell Health and Oxford University Hospitals.As of September 30, 2024, Nanox maintained a strong financial position with $57.1 million in cash, cash equivalents and marketable securities. The company is actively working with FDA on full body scanning approval and pursuing CE Mark designation in Europe, which management believes will significantly expand their addressable market.
Nanox reported Q3 2024 revenue of $3.0 million, up from $2.5 million in Q3 2023, driven by growth in teleradiology services and AI solutions. The company posted a net loss of $13.6 million, an improvement from $21.4 million loss in the prior year period, primarily due to reduced impairment expenses.The company continued expanding its US sales and support teams while making progress in global deployment of Nanox.ARC systems. The Nanox.AI business secured new distribution agreements with SpinexMedical and extended partnerships with major healthcare providers including Corewell Health and Oxford University Hospitals.As of September 30, 2024, Nanox maintained a strong financial position with $57.1 million in cash, cash equivalents and marketable securities. The company is actively working with FDA on full body scanning approval and pursuing CE Mark designation in Europe, which management believes will significantly expand their addressable market.
Nanox報告2024年第三季度營業收入爲300萬元,比2023年第三季度的250萬元增長,主要得益於遠程放射學服務和人工智能解決方案的增長。該公司淨虧損爲1360萬元,較去年同期的2140萬元虧損有所改善,主要由於減值費用減少。該公司繼續擴展其在美國的銷售和支持團隊,同時在Nanox.ARC系統的全球部署方面取得進展。Nanox.AI業務與SpinexMedical達成新的分銷協議,並與主要醫療服務提供商如Corewell Health和牛津大學醫院延長了合作伙伴關係。截至2024年9月30日,Nanox保持強勁的財務狀況,現金、現金等價物和可交易證券總額爲5710萬元。該公司正在與FDA積極合作,申請全身掃描批准,並在歐洲追求CE認證,管理層認爲這將顯著擴大他們的可觸及市場。
Nanox報告2024年第三季度營業收入爲300萬元,比2023年第三季度的250萬元增長,主要得益於遠程放射學服務和人工智能解決方案的增長。該公司淨虧損爲1360萬元,較去年同期的2140萬元虧損有所改善,主要由於減值費用減少。該公司繼續擴展其在美國的銷售和支持團隊,同時在Nanox.ARC系統的全球部署方面取得進展。Nanox.AI業務與SpinexMedical達成新的分銷協議,並與主要醫療服務提供商如Corewell Health和牛津大學醫院延長了合作伙伴關係。截至2024年9月30日,Nanox保持強勁的財務狀況,現金、現金等價物和可交易證券總額爲5710萬元。該公司正在與FDA積極合作,申請全身掃描批准,並在歐洲追求CE認證,管理層認爲這將顯著擴大他們的可觸及市場。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息